SCHEMBL2707320

SCHEMBL2707320

CC1(C)OB(c2ccc(-c3ccc(B4OC(C)(C)C(C)(C)O4)cc3)cc2)OC1(C)C

nearest known ligand 0.83

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LIPG Q9Y5X9 13/20 0.83
LPL P06858 12/20 0.83
CA1 P00915 2/20 0.52
CA2 P00918 2/20 0.52
CA9 Q16790 2/20 0.52
CA12 O43570 1/20 0.52
CA3 P07451 1/20 0.52
CA4 P22748 1/20 0.52
CA6 P23280 1/20 0.52
CA5A P35218 1/20 0.52
CA7 P43166 1/20 0.52
CA14 Q9ULX7 1/20 0.52
CA5B Q9Y2D0 1/20 0.52
F11 P03951 2/20 0.50
ESR2 Q92731 1/20 0.46
SNCA P37840 1/20 0.44
P4HB P07237 1/20 0.44
F2 P00734 1/20 0.42
PRSS1 P07477 1/20 0.42
PRSS2 P07478 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24608995 1.00 LIPG (0.83) LIPGLPLCA1CA2CA9
SCHEMBL12681706 0.93 LIPG (0.74) LIPGLPLCA1CA2CA9
SCHEMBL28389622 0.93 LIPG (0.88) LIPGLPLCA1CA2CA9
SCHEMBL228212 0.92 LPL (0.71) LIPGLPLCA1CA2CA9
SCHEMBL18134357 0.91 LIPG (1.00) LIPGLPLCA1CA2CA9
SCHEMBL476870 0.91 LIPG (1.00) LIPGLPLCA1CA2CA9
SCHEMBL18270366 0.91 LIPG (1.00) LIPGLPLCA1CA2CA9
SCHEMBL10021061 0.91 LIPG (1.00) LIPGLPLCA1CA2CA9
SCHEMBL4470995 0.91 LIPG (0.71) LIPGLPLCA1CA2CA9
SCHEMBL4470992 0.89 LIPG (0.69) LIPGLPLCA1CA2CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116870962-A Multiphase nitrogen-containing ligand modified supported ruthenium catalyst and preparation and application thereof 中国科学院兰州化学物理研究所 2023-10-13 CN claimed
CN-114602425-B Plasma activated carbon regeneration method taking hydrogen peroxide as secondary excitation object 上海鎏明科技有限公司 2023-05-12 CN claimed
CN-114602425-A Plasma activated carbon regeneration method using hydrogen peroxide as secondary excitation object 上海鎏明科技有限公司 2022-06-10 CN claimed
EP-4051667-B1 HETEROCYCLIC CARBOXYLATE COMPOUNDS AS GLYCOLATE OXIDASE INHIBITORS LILAC THERAPEUTICS INC (US) 2026-01-28 EP disclosed
US-20250064787-A1 Heterocyclic Carboxylate Compounds as Glycolate Oxidase Inhibitors LILAC THERAPEUTICS INC (US) 2025-02-27 US disclosed
EP-4470538-A2 HETEROCYCLIC CARBOXYLATE COMPOUNDS AS GLYCOLATE OXIDASE INHIBITORS Lilac Therapeutics, Inc. (US) 2024-12-04 EP disclosed
US-12071503-B2 Method for preparing and repairing covalent organic framework materials ZHEJIANG UNIVERSITY (CN) 2024-08-27 US disclosed
US-11806335-B2 Heterocyclic carboxylate compounds as glycolate oxidase inhibitors Lilac Therapeutics, Inc. (US) 2023-11-07 US disclosed
US-11806335-B2 Heterocyclic carboxylate compounds as glycolate oxidase inhibitors Lilac Therapeutics, Inc. (US) 2023-11-07 US disclosed
US-11806335-B2 Heterocyclic carboxylate compounds as glycolate oxidase inhibitors Lilac Therapeutics, Inc. (US) 2023-11-07 US disclosed
CN-116870962-A Multiphase nitrogen-containing ligand modified supported ruthenium catalyst and preparation and application thereof 中国科学院兰州化学物理研究所 2023-10-13 CN disclosed
US-20110168992-A1 NOVEL COMPOUND, METHOD FOR PREPARING SAME AND ORGANIC ELECTRONIC DEVICE USING SAME LG CHEM, LTD. (KR) 2011-07-14 US disclosed
US-20110168992-A1 NOVEL COMPOUND, METHOD FOR PREPARING SAME AND ORGANIC ELECTRONIC DEVICE USING SAME LG CHEM, LTD. (KR) 2011-07-14 US disclosed
US-20100310512-A1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. 2010-12-09 US disclosed
US-20100310512-A1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. 2010-12-09 US disclosed
WO-2010132601-A1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. (US) 2010-11-18 WO disclosed
US-20090091244-A1 AMINE COMPOUND, ORGANIC LIGHT-EMITTING DEVICE, AND ORGANIC BLUE-LIGHT-EMITTING DEVICE CANON KABUSHIKI KAISHA (JP) 2009-04-09 US disclosed
US-20090091244-A1 AMINE COMPOUND, ORGANIC LIGHT-EMITTING DEVICE, AND ORGANIC BLUE-LIGHT-EMITTING DEVICE CANON KABUSHIKI KAISHA (JP) 2009-04-09 US disclosed
US-20090048413-A1 Method for Production of Conjugated Polymer SUMITOMO CHEMICAL COMPANY, LIMITED 2009-02-19 US disclosed
EP-1997844-A1 METHOD FOR PRODUCTION OF CONJUGATED POLYMER Sumitomo Chemical Company, Limited (JP) 2008-12-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11806335-B2 Heterocyclic carboxylate compounds as glycolate oxidase inhibitors UGDH, PGD, PNPO LIPG 197/4885LPL 660/4885CA1 611/4885
US-20090091244-A1 AMINE COMPOUND, ORGANIC LIGHT-EMITTING DEVICE, AND ORGANIC BLUE-LIGHT-EMITTING DEVICE TYR, AOC2, CRY1 LIPG 2758/4885LPL 1831/4885CA1 4347/4885
US-20100310512-A1 ANTIVIRAL COMPOUNDS MAVS, EIF2AK2, ZC3HAV1 LIPG 1280/4885LPL 2383/4885CA1 4745/4885
US-20110168992-A1 NOVEL COMPOUND, METHOD FOR PREPARING SAME AND ORGANIC ELECTRONIC DEVICE USING SAME OR10J3, USE1, NOTUM LIPG 1928/4885LPL 3043/4885CA1 4266/4885
US-20250064787-A1 Heterocyclic Carboxylate Compounds as Glycolate Oxidase Inhibitors GLS, DUOX1, HAO1 LIPG 1139/4885LPL 1856/4885CA1 205/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.